Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLS-W1100
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
GLS-W1100 is a live biotherapeutic product (LBP) consisting of the bacterium *Lactobacillus crispatus*, developed by Hangzhou Grand Biopharmaceutical (a subsidiary of China Grand Pharmaceutical and Healthcare Holdings) for the treatment of bacterial vaginosis (BV). The drug is designed to restore the natural vaginal microecology, which is typically dominated by *Lactobacillus* species in healthy individuals. By colonizing the vaginal environment, *L. crispatus* produces lactic acid to maintain a low pH and secretes antimicrobial substances such as hydrogen peroxide and bacteriocins, which collectively inhibit the overgrowth of anaerobic pathogens like *Gardnerella vaginalis*. GLS-W1100 is currently in Phase 2 clinical development in China, aiming to provide a biological alternative or adjunct to traditional antibiotic therapy for BV and its recurrence.
- Other names
- Lactobacillus crispatus live biotherapeutic product
Beyond the preview
Go deeper on GLS-W1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLS-W1100.